EMERGENT BIOSOLUTIONS INC. (EBS)
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical